Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00162149 | ATV/Ritonavir Nevirapine Interaction (USPAC) | PHASE1 | COMPLETED | 46 | — | — | Oct 1, 2005 | Jul 1, 2006 | Apr 8, 2011 | 3 | United States, United Kingdom |
| Arm | Type | Description |
|---|---|---|
| A1 | NO_INTERVENTION | - |
| A2 | EXPERIMENTAL | - |
| A3 | EXPERIMENTAL | - |
| B1 | NO_INTERVENTION | - |
| Name | Type | Description |
|---|---|---|
| Nevirapine | DRUG | Tablets, Oral, 200 mg, Twice daily, 3 days. |
| Nevirapine + Atazanavir/Ritonavir | DRUG | Tablets + Capsules/Capsules, Oral, 200 mg + 300/100 mg, twice daily + once daily, 10 days. |
| Atazanavir + Ritonavir | DRUG | Capsules/capsules, Oral, 300/100 mg, once daily, 10 days. |
Inclusion Criteria: * signed informed consent form * For Cohort 1, HIV-infected subjects receiving nevirapine 200 mg twice-daily and 2 to 3 NRTIs for at least 6 weeks * For Cohort 2, HIV-infected subjects receiving atazanavir 300 mg and ritonavir 100 mg once-daily and 2 to 3 NRTIs for at least 6 we...